{
    "nctId": "NCT05180851",
    "briefTitle": "Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study",
    "officialTitle": "Safety and Efficacy of Recombinant L-IFN Adenovirus Injection in Relapsed/Refractory Solid Tumors: a Single/Multicenter, Dose-increasing, Cohort Extension Clinical Study",
    "overallStatus": "UNKNOWN",
    "conditions": "Head and Neck Cancer, Melanoma, Breast Cancer, Bladder Cancer, Ovarian Carcinoma, Cervical Carcinoma, Lung Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 28,
    "primaryOutcomeMeasure": "Dose Limiting Toxicities (DLT)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Male or female aged \u2265 18 and \u2264 75 years;\n2. Patients with advanced malignant solid tumors, histologically or cytologically confirmed, who have failed standard therapy, have no standard therapy, are not eligible for standard therapy at this stage, or have refused standard therapy\uff1b\n3. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1), the length of non-lymph node lesion \u226510 mm or the short diameter of lymph node lesion \u226515 mm according to CT or MRI cross-sectional images;CT scan of the longest axis of measurable lesions \u226510 mm (CT scan thickness \u22645 mm)\uff1b\n4. There were injectable tumor lesions that met the requirements of the current dose group, including superficial lesions and deep lesions that could be injected under the guidance of B-ultrasound /CT\uff1b\n5. ECOG score of 0 \\~ 2;\n6. Sufficient hematopoietic capacity: ANC \u22651.0 \u00d710\\^9/L (no short-acting albino within 1 week, no long-acting albino within 2 weeks), platelet count \u226575 \u00d710\\^9/L, HGB \\> 80 g/L (no blood transfusion within 2 weeks)\uff1b\n7. Adequate liver and kidney function: AST and ALT \u22643 times ULN in patients without liver metastasis, \u22645 times ULN in patients with liver metastasis; Total bilirubin \u22641.5 ULN (excluding hyperbilirubinemia or hyperbilirubin of non-liver origin);Creatinine \u22642.0 ULN and creatinine clearance and creatinine clearance \u226540 mL/min;\n8. Eligible and fertile patients (male and female) must agree to use a reliable contraceptive method during the trial and for at least 90 days after the last dose; Women of childbearing age (15-49 years) must have a negative pregnancy test within 7 days before starting treatment;\n9. PT or INR \\<1.5 ULN, and APTT \\<1.5 ULN\uff1b\n10. Expect to live at least 12 weeks\uff1b\n\nExclusion Criteria:\n\n1. Received any antineoplastic therapy within 2 weeks prior to initial treatment\uff1b\n2. Systemic diseases that have not been stably controlled after treatment, such as diabetes, serious organic cardiovascular and cerebrovascular diseases, cardiac insufficiency, hypertension, heart block above \u2171 degree, myocardial infarction within 6 months, cerebral infarction within 6 months, etc.\n3. Pregnancy or lactation;\n4. Uncontrolled infectious diseases, such as baseline HBV DNA\u22652000 IU/ml, anti-HIV positive, HCV-RNA positive;\n5. Other active infections of significant clinical significance;\n6. Subjects with other active malignancies within the past 5 years, such as basal or squamous skin cancer, superficial bladder cancer, or breast cancer in situ, that have been completely cured and do not require follow-up treatment are excluded;\n7. Severe autoimmune diseases such as ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, autoimmune vasculitis, or Wegener's granuloma require long-term (more than 2 months) systemic immunosuppressive therapy, but subjects with the following conditions are admitted:\n\n   Autoimmune hypothyroidism requiring only hormone replacement therapy; Skin disorders that do not require systemic treatment (e.g., eczema, a rash of less than 10% of the body surface);\n8. Subjects with allergic constitution, allergy to immunotherapy or related drugs;\n9. Organ failure; Coronary heart: grades \u2172 and \u2173;Or hypertension that cannot be controlled by standard treatment, a history of myocarditis or myocardial infarction within one year; Gallo liver: achieves grade C on the Child-Turcotte-Pugh liver function scale; Gallonic kidney: renal failure and uremia; Lung: symptoms of severe respiratory failure; Brain unconsciously: people with consciousness disorder have active brain metastases;\n10. Patients with active bleeding and thrombotic diseases requiring treatment;\n11. Patients with uncontrollable pleural and abdominal effusion requiring clinical treatment or intervention;\n12. Subjects requiring systemic corticosteroids (equivalent to \\>10 mg prednisone/day) within 14 days prior to enrollment or during the study period;\n\n    The following conditions are allowed to join the group:\n\n    Allow subjects to use topical or inhaled corticosteroids; Allows short-term (\u22647 days) use of glucocorticoids for the prevention or treatment of non-autoimmune allergic diseases;\n13. Subject suffering from any mental illness, including dementia, altered mental state, that may affect informed consent and understanding of the relevant questionnaire;\n14. Participated in clinical trials of other drugs or medical devices within 4 weeks;\n15. If the investigator determines that they have a serious and uncontrollable disease or other conditions that may affect their acceptance of this study, they are not considered suitable for this study.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}